HUP0203976A2 - Adenozin a3 receptor antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Adenozin a3 receptor antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0203976A2
HUP0203976A2 HU0203976A HUP0203976A HUP0203976A2 HU P0203976 A2 HUP0203976 A2 HU P0203976A2 HU 0203976 A HU0203976 A HU 0203976A HU P0203976 A HUP0203976 A HU P0203976A HU P0203976 A2 HUP0203976 A2 HU P0203976A2
Authority
HU
Hungary
Prior art keywords
group
carbon atoms
straight
atom
hydrogen atom
Prior art date
Application number
HU0203976A
Other languages
English (en)
Inventor
Kinga Boér
Géza Tímári
Sándor Bátori
Zoltán Kapui
Endre Mikus
Péter Arányi
Mária Balogh
László Balázs
NAGY Lajos T.
Katalin Gerber
Katalin Urbán-Szabó
Szeredi Judit Vargáné
Erzsébet Walcz
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Priority to HU0203976A priority Critical patent/HUP0203976A3/hu
Publication of HU0203976D0 publication Critical patent/HU0203976D0/hu
Priority to MEP-190/08A priority patent/MEP19008A/xx
Priority to CNB2003801062293A priority patent/CN1332960C/zh
Priority to AU2003282263A priority patent/AU2003282263B2/en
Priority to SI200330299T priority patent/SI1560828T1/sl
Priority to UAA200505875A priority patent/UA78889C2/uk
Priority to KR1020057008683A priority patent/KR20050088291A/ko
Priority to NZ540029A priority patent/NZ540029A/en
Priority to ES03773882T priority patent/ES2263039T3/es
Priority to AT03773882T priority patent/ATE325123T1/de
Priority to JP2004552920A priority patent/JP4533148B2/ja
Priority to PT03773882T priority patent/PT1560828E/pt
Priority to YUP-2005/0364A priority patent/RS51320B/sr
Priority to DE60305058T priority patent/DE60305058T2/de
Priority to BR0316355-5A priority patent/BR0316355A/pt
Priority to MXPA05005198A priority patent/MXPA05005198A/es
Priority to PL376837A priority patent/PL376837A1/pl
Priority to EP03773882A priority patent/EP1560828B9/en
Priority to DK03773882T priority patent/DK1560828T3/da
Priority to PCT/HU2003/000095 priority patent/WO2004046146A1/en
Priority to CA2505910A priority patent/CA2505910C/en
Priority to EA200500830A priority patent/EA007595B1/ru
Priority to ARP030104200A priority patent/AR041968A1/es
Priority to TW092131901A priority patent/TWI248934B/zh
Publication of HUP0203976A2 publication Critical patent/HUP0203976A2/hu
Publication of HUP0203976A3 publication Critical patent/HUP0203976A3/hu
Priority to IL168516A priority patent/IL168516A/en
Priority to TNP2005000133A priority patent/TNSN05133A1/en
Priority to ZA200503807A priority patent/ZA200503807B/en
Priority to US11/130,429 priority patent/US7419977B2/en
Priority to IS7874A priority patent/IS2456B/is
Priority to NO20052866A priority patent/NO20052866L/no
Priority to MA28334A priority patent/MA27501A1/fr
Priority to CO05057645A priority patent/CO5690577A2/es
Priority to HR20050540A priority patent/HRP20050540A2/xx
Priority to HK05109885A priority patent/HK1077819A1/xx
Priority to CY20061101054T priority patent/CY1105180T1/el
Priority to US12/140,512 priority patent/US7709489B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)

Abstract

A találmány tárgya (I) általános képletű vegyületek, ahol R1 jelentésehidrogénatom, vagy 1-4 szénatomos egyenes vagy elágazó szénláncúalkilcsoport; R2 jelentése hidrogénatom, vagy 1-4 szénatomos egyenesvagy elágazó szénláncú alkilcsoport; R3 jelentése hidrogénatom, 1-4szénatomos egyenes vagy elágazó szénláncú alkilcsoport, 3-6 szénatomoscikloalkilcsoport, adott esetben egy vagy több 1-4 szénatomos egyenesvagy elágazó szénláncú alkilcsoporttal, 1-4 szénatomos egyenes vagyelágazó szénláncú alkoxicsoporttal, vagy halogénatommal szubsztituáltfenil-, tienil-, vagy furilcsoport, adott esetben egy vagy több 1-4szénatomos egyenes vagy elágazó szénláncú alkilcsoporttal, 1-4szénatomos egyenes vagy elágazó szénláncú alkoxicsoporttal, vagyhalogénatommal szubsztituált, egy vagy két vagy három nitrogénatomottartalmazó 5 vagy 6 tagú heteroaromás gyűrű,vagy egy nitrogénatomot ésegy oxigénatomot tartalmazó 5 tagú heteroaromás gyűrű. R4, R5, R6 ésR7 jelentése egymástól függetlenül hidrogénatom, 1-4 szénatomosegyenes vagy elágazó szénláncú alkilcsoport, 1-4 szénatomos egyenesvagy elágazó szénláncú alkoxicsoport, hidroxicsoport, vagyhalogénatom, vagy R4 és R7 jelentése hidrogénatom és R5 és R6együttesen metiléndioxicsoportot képeznek; R8 jelentése hidrogénatom,cianocsoport, aminokarbonilcsoport, 1-4 szénatomosalkoxikarbonilcsoport, vagy karboxicsoport; R9 és Rl0 jelentéseegymástól függetlenül hidrogénatom, 1-4 szénatomos egyenes vagyelágazó szénláncú alkilcsoport, 3-6 szénatomos cikloalkilcsoport. Xjelentése -CH2- csoport, -NH- csoport, -NR11- csoport, vagy kénatom,vagy oxigénatom, vagy szulfocsoport vagy szulfoxicsoport - ahol R11jelentése 1-4 szénatomos egyenes vagy elágazó szénláncú alkilcsoport,vagy 3-6 szénatomos cikloalkilcsoport-; Z jelentése oxigénatom,kénatom, -NH- csoport vagy -NR12-csoport - ahol R12 jelentése 1-4szénatomos egyenes vagy elágazó szénláncú alkilcsoport, vagy 3-6szénatomos cikloalkilcsoport-; n értéke nulla, 1 vagy 2; m értékenulla, 1, 2, vagy 3 o értéke nulla, 1, 2, vagy 3 p értéke nulla vagy 1r értéke nulla vagy 1, azzal a megkötéssel, hogy m és o közül legalábbaz egyik értéke nullától eltérő, valamint sóik, szolvátjaik,optikailag aktív izomerjeik és ezek sói és szolvátjai. A találmánykiterjed a vegyületek előállítására, ezeket tartalmazógyógyszerkészítményekre is. Ó
HU0203976A 2002-11-15 2002-11-15 Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them HUP0203976A3 (en)

Priority Applications (36)

Application Number Priority Date Filing Date Title
HU0203976A HUP0203976A3 (en) 2002-11-15 2002-11-15 Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
YUP-2005/0364A RS51320B (sr) 2002-11-15 2003-11-11 Derivati imidazohinolina kao veznici a3 receptora adenozina
DK03773882T DK1560828T3 (da) 2002-11-15 2003-11-11 Imidazoquinolinderivater som adenosin-A3-receptorligander
CA2505910A CA2505910C (en) 2002-11-15 2003-11-11 Imidazoquinoline derivatives as adenosine a3 receptor ligands
AU2003282263A AU2003282263B2 (en) 2002-11-15 2003-11-11 Imidazoquinoline derivatives as adenosine A3 receptor ligands
PCT/HU2003/000095 WO2004046146A1 (en) 2002-11-15 2003-11-11 Imidazoquinoline derivatives as adenosine a3 receptor ligands
UAA200505875A UA78889C2 (en) 2002-11-15 2003-11-11 Imidazoquinoline derivatives as an adenosine a3 receptor ligands
KR1020057008683A KR20050088291A (ko) 2002-11-15 2003-11-11 아데노신 ａ３ 수용체 리간드로서의 이미다조퀴놀린 유도체
NZ540029A NZ540029A (en) 2002-11-15 2003-11-11 Imidazoquinoline derivatives as adenosine A3 receptor ligands
ES03773882T ES2263039T3 (es) 2002-11-15 2003-11-11 Derivados de imidazoquinolina como ligandos del receptor a3 de adenosina.
AT03773882T ATE325123T1 (de) 2002-11-15 2003-11-11 Imidazoquinoline derivate als adenosine a3 rezeptor liganden
JP2004552920A JP4533148B2 (ja) 2002-11-15 2003-11-11 アデノシンａ３受容体リガンドとしてのイミダゾキノリン誘導体
PT03773882T PT1560828E (pt) 2002-11-15 2003-11-11 Derivados de imidazoquinolina como ligandos receptores a3 da adenosina
CNB2003801062293A CN1332960C (zh) 2002-11-15 2003-11-11 作为腺苷a3受体配体的咪唑并喹啉衍生物
DE60305058T DE60305058T2 (de) 2002-11-15 2003-11-11 Imidazoquinoline derivate als adenosine a3 rezeptor liganden
BR0316355-5A BR0316355A (pt) 2002-11-15 2003-11-11 Derivados de imidazoquinolina como ligantes de receptores de adenosina a3
MXPA05005198A MXPA05005198A (es) 2002-11-15 2003-11-11 Derivados de imidazoquinolina, como ligandos del receptor a3 de adenosina.
PL376837A PL376837A1 (pl) 2002-11-15 2003-11-11 Pochodne imidazochinoliny jako ligandy receptora adenozyny A3
EP03773882A EP1560828B9 (en) 2002-11-15 2003-11-11 Imidazoquinoline derivatives as adenosine a3 receptor ligands
MEP-190/08A MEP19008A (en) 2002-11-15 2003-11-11 Imidazoquinoline derivatives as adenosine a3 receptor ligands
SI200330299T SI1560828T1 (sl) 2002-11-15 2003-11-11 Imidazokinolinski derivati kot adenozin A3 receptorski ligandi
EA200500830A EA007595B1 (ru) 2002-11-15 2003-11-11 Производные имидазохинолина в качестве лигандов аденозиновых арецепторов
ARP030104200A AR041968A1 (es) 2002-11-15 2003-11-14 Compuestos derivados de imidazol como ligandos del receptor de adenosina
TW092131901A TWI248934B (en) 2002-11-15 2003-11-14 Compounds of adenosine A3 receptor ligands and the process for manufacturing the same
TNP2005000133A TNSN05133A1 (en) 2002-11-15 2005-05-10 Imidazoquinoline derivatives as adenosine a3 receptor ligands
IL168516A IL168516A (en) 2002-11-15 2005-05-10 Imidazoquinoline derivatives as adenosine a3 receptor ligands
ZA200503807A ZA200503807B (en) 2002-11-15 2005-05-11 Imidazoquinoline derivatives as adenosine A3 receptor ligands
US11/130,429 US7419977B2 (en) 2002-11-15 2005-05-16 Imidazoquinoline derivatives as adenosine A3 receptor ligands
IS7874A IS2456B (is) 2002-11-15 2005-05-31 Ímídasókínólínafleiður sem adenósín A3 viðtakabindlar
NO20052866A NO20052866L (no) 2002-11-15 2005-06-13 Imidazokinolinderivater som adenosin A3 reseptorligander
MA28334A MA27501A1 (fr) 2002-11-15 2005-06-13 Derives d'imidazoquinoline en tant que ligands recepteurs de l'adenosine a3
HR20050540A HRP20050540A2 (en) 2002-11-15 2005-06-14 Imidazoquinoline derivatives as adenosine a3 receptor ligands
CO05057645A CO5690577A2 (es) 2002-11-15 2005-06-14 Derivados de imidazoquinolina como ligandos receptores de adenosina a3
HK05109885A HK1077819A1 (en) 2002-11-15 2005-11-07 Imidazoquinoline derivatives as adenosine a3 receptor ligands
CY20061101054T CY1105180T1 (el) 2002-11-15 2006-07-28 Παραγωγα ιμιδαζοκινολινης ως α3 συνδετες υποδοχεων αδενοσινης
US12/140,512 US7709489B2 (en) 2002-11-15 2008-06-17 Imidazoquinoline derivatives as adenosine A3 receptor ligands

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0203976A HUP0203976A3 (en) 2002-11-15 2002-11-15 Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them

Publications (3)

Publication Number Publication Date
HU0203976D0 HU0203976D0 (en) 2003-01-28
HUP0203976A2 true HUP0203976A2 (hu) 2004-07-28
HUP0203976A3 HUP0203976A3 (en) 2004-08-30

Family

ID=90001561

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203976A HUP0203976A3 (en) 2002-11-15 2002-11-15 Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them

Country Status (35)

Country Link
US (2) US7419977B2 (hu)
EP (1) EP1560828B9 (hu)
JP (1) JP4533148B2 (hu)
KR (1) KR20050088291A (hu)
CN (1) CN1332960C (hu)
AR (1) AR041968A1 (hu)
AT (1) ATE325123T1 (hu)
AU (1) AU2003282263B2 (hu)
BR (1) BR0316355A (hu)
CA (1) CA2505910C (hu)
CO (1) CO5690577A2 (hu)
CY (1) CY1105180T1 (hu)
DE (1) DE60305058T2 (hu)
DK (1) DK1560828T3 (hu)
EA (1) EA007595B1 (hu)
ES (1) ES2263039T3 (hu)
HK (1) HK1077819A1 (hu)
HR (1) HRP20050540A2 (hu)
HU (1) HUP0203976A3 (hu)
IL (1) IL168516A (hu)
IS (1) IS2456B (hu)
MA (1) MA27501A1 (hu)
ME (1) MEP19008A (hu)
MX (1) MXPA05005198A (hu)
NO (1) NO20052866L (hu)
NZ (1) NZ540029A (hu)
PL (1) PL376837A1 (hu)
PT (1) PT1560828E (hu)
RS (1) RS51320B (hu)
SI (1) SI1560828T1 (hu)
TN (1) TNSN05133A1 (hu)
TW (1) TWI248934B (hu)
UA (1) UA78889C2 (hu)
WO (1) WO2004046146A1 (hu)
ZA (1) ZA200503807B (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0105406A3 (en) * 2001-12-21 2003-12-29 Sanofi Aventis Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
HUP0400812A2 (en) * 2004-04-19 2006-02-28 Sanofi Aventis Crystalline forms of 2-amino-3-cyano-quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
HUP0700395A2 (en) * 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
EP2456419B1 (en) 2009-07-21 2016-11-23 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
EP2950649B1 (en) 2013-02-01 2020-03-04 Wellstat Therapeutics Corporation Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
KR101820909B1 (ko) * 2017-07-07 2018-01-23 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 만성신장질환 예방 및 치료용 약학적 조성물
MA50250A (fr) 2017-09-15 2020-07-22 Forma Therapeutics Inc Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
BR112020026783A2 (pt) 2018-06-29 2021-03-30 Forma Therapeutics, Inc. Inibição da proteína de ligação creb (cbp)
BR112021016921A2 (pt) * 2019-03-15 2021-11-03 Forma Therapeutics Inc Inibição de proteína de ligação a elemento responsivo a amp cíclico (creb)
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4075343A (en) * 1976-09-13 1978-02-21 Pfizer Inc. Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof
GB1596652A (en) * 1977-01-20 1981-08-26 Roussel Lab Ltd Imidazo (1,2-a) quinoline-2-carboxylic acid and derivatives
US4644002A (en) * 1979-02-09 1987-02-17 Roussel Uclaf Imidazo[2,1-C]quinolines, useful as antiallergic agents
IL59104A (en) * 1979-02-09 1984-02-29 Roussel Uclaf Heterotricyclic derivatives,process for their preparation and pharmaceutical compositions incorporating them
FR2448541A1 (fr) * 1979-02-09 1980-09-05 Roussel Uclaf Nouveaux derives de l'oxoimidazoquinoxaline et leurs sels, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
CA2336967C (en) * 1998-07-10 2010-06-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
KR20020046285A (ko) * 1999-09-28 2002-06-20 고마즈 교우이찌 트리아조로푸린 유도체,그 유도체를 함유하는 의약 조성물및 아데노신 에이 3 수용체 친화제
US7160890B2 (en) * 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
WO2002057267A1 (en) * 2000-12-01 2002-07-25 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof
RS95003A (en) * 2001-05-31 2007-02-05 Sanofi-Aventis, Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
HUP0105407A3 (en) * 2001-12-21 2004-04-28 Sanofi Aventis Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0105406A3 (en) * 2001-12-21 2003-12-29 Sanofi Aventis Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EP1560828B1 (en) 2006-05-03
IS7874A (is) 2005-05-31
KR20050088291A (ko) 2005-09-05
IS2456B (is) 2008-11-15
WO2004046146A1 (en) 2004-06-03
HRP20050540A2 (en) 2005-08-31
TWI248934B (en) 2006-02-11
RS20050364A (en) 2007-08-03
CO5690577A2 (es) 2006-10-31
PT1560828E (pt) 2006-08-31
US20050234056A1 (en) 2005-10-20
US20080255110A1 (en) 2008-10-16
ES2263039T3 (es) 2006-12-01
JP2006515572A (ja) 2006-06-01
CN1726213A (zh) 2006-01-25
PL376837A1 (pl) 2006-01-09
DE60305058D1 (de) 2006-06-08
UA78889C2 (en) 2007-04-25
NZ540029A (en) 2007-01-26
EP1560828A1 (en) 2005-08-10
US7419977B2 (en) 2008-09-02
JP4533148B2 (ja) 2010-09-01
SI1560828T1 (sl) 2006-08-31
AU2003282263A1 (en) 2004-06-15
HU0203976D0 (en) 2003-01-28
IL168516A (en) 2011-05-31
RS51320B (sr) 2010-12-31
CY1105180T1 (el) 2010-03-03
HK1077819A1 (en) 2006-02-24
BR0316355A (pt) 2005-09-27
CN1332960C (zh) 2007-08-22
EA007595B1 (ru) 2006-12-29
EP1560828B9 (en) 2007-02-14
DE60305058T2 (de) 2006-12-14
TW200413369A (en) 2004-08-01
EA200500830A1 (ru) 2005-10-27
MXPA05005198A (es) 2005-08-18
US7709489B2 (en) 2010-05-04
ZA200503807B (en) 2006-08-30
TNSN05133A1 (en) 2007-05-14
CA2505910C (en) 2010-07-13
CA2505910A1 (en) 2004-06-03
AU2003282263B2 (en) 2009-05-14
AR041968A1 (es) 2005-06-01
NO20052866D0 (no) 2005-06-13
DK1560828T3 (da) 2006-09-04
HUP0203976A3 (en) 2004-08-30
MA27501A1 (fr) 2005-08-01
ATE325123T1 (de) 2006-06-15
NO20052866L (no) 2005-06-13
MEP19008A (en) 2010-06-10

Similar Documents

Publication Publication Date Title
CO5070570A1 (es) DERIVADOS DE TIROSINA COMO ACTIVADORES DE hPPAR Y hPPARalfa Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE
HUP0203976A2 (hu) Adenozin a3 receptor antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EA200600364A1 (ru) Производные (тио)карбамоилциклогексана в качестве антагонистов d/dрецептора
KR927003052A (ko) 2-아릴티아졸 유도체 및 그의 약제학적 조성물
PT1140916E (pt) Acetais heteroarilo ciclicos
HUP0402026A2 (hu) 5,6-Diaril-pirazin-2-amid-származékok mint CB1 antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
WO2003024967A3 (en) Indolizines as kinase protein inhibitors
DE60228406D1 (de) PYRAZOLOÄ3,4-dÜPYRIMIDINDERIVATE UND IHRE VERWENDUNG ALS ANTAGONISTEN DES PURINERGEN REZEPTORS
NO20062269L (no) Pyridin-karboksylsyrederivater som glucokinasemodulatorer
TW200510441A (en) Novel compounds
RS49921B (sr) Terapeutski biaril derivati
HUP0002050A2 (hu) Szubsztituált imidazolvegyületek, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
EA200000731A1 (ru) Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
SE8303824D0 (sv) N-imidazolyl derivatives of bicyclic compounds and process for their preparation
DE69003200D1 (de) Arylsubstituierte Aminderivate verwendbar in der Krebstherapie.
HUP9802865A2 (hu) N-(szubsztituált fenil-)-pirazol-származékok, előállításuk és alkalmazásuk, a vegyületeket hatóanyagként tartalmazó parazitaellenes készítmények
HUP0301167A2 (hu) Neurológiai rendellenességek kezelésére felhasználható szulfonil-pirrolidin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0203739A2 (hu) A hatos-gyűrűn helyettesített biciklikus imidazo-3-il-amin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HRP20031091B1 (en) Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
HUP0105407A2 (hu) Triazolo[1,5-a]kinolinszármazékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények, valamint intermedierek
TW200510320A (en) Aminoquinoline derivatives and their use as adenosine A3 ligands
HUP0000729A2 (hu) Új amidszármazékok és ezeket tartalmazó gyógyszerkészítmények
HUP0105406A2 (hu) Imidazo[1,2-a]kinolinszármazékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények, valamint intermedierek
CO4950607A1 (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg c o a reductasa para el tratamiento del cancer

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished